Incyte Genomics Inc
INCY Real Time Price USD
N/A
N/A
N/A
...
Overview
Financials
Insiders
Institutions
Government
Ownership
Income
Balance Sheet
Cash Flow
INCY Income Statement
INCY Balance Sheet
INCY Cash Flow
Recent trades of INCY by members of U.S. Congress
INCY Stock Insider Trading Activity
|
Name
|
Type
|
Shares
|
Price
|
Shares Held
|
Date
|
Reported
|
|---|
INCY Stock Institutional Owners
|
Investor
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
INCY Derivatives Institutional Owners
|
Investor
|
Type
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
Recently reported changes by institutional investors
Quarterly net insider trading by INCY's directors and management
Government lobbying spending instances
-
$220,000 Oct 21, 2024 Issue: Medicare/Medicaid
-
$300,000 Jul 22, 2024 Issue: Medicare/Medicaid
-
$200,000 Apr 22, 2024 Issue: Medicare/Medicaid
-
$460,000 Apr 22, 2024 Issue: Medicare/Medicaid
-
$360,000 Oct 20, 2023 Issue: Medicare/Medicaid
-
$220,000 Jul 20, 2023 Issue: Medicare/Medicaid
-
$180,000 Jan 20, 2023 Issue: Copyright/Patent/Trademark Medicare/Medicaid
-
$220,000 Oct 20, 2022 Issue: Copyright/Patent/Trademark Medicare/Medicaid
-
$200,000 Jul 21, 2022 Issue: Taxation/Internal Revenue Code Medicare/Medicaid
-
$280,000 Apr 20, 2022 Issue: Medicare/Medicaid
-
$110,000 Jan 21, 2022 Issue: MEDICARE/MEDICAID
-
$190,000 Oct 20, 2021 Issue: MEDICARE/MEDICAID
-
$500,000 Jul 20, 2021 Issue: MEDICARE/MEDICAID
-
$200,000 Apr 20, 2021 Issue: MEDICARE/MEDICAID
-
$50,000 Jan 21, 2021 Issue: Health Issues
-
$50,000 Jan 20, 2021 Issue: None
-
$20,000 Jan 19, 2021 Issue: None
-
$50,000 Oct 20, 2020 Issue: Health Issues
-
$50,000 Oct 20, 2020 Issue: MEDICARE/MEDICAID
-
$50,000 Jul 20, 2020 Issue: MEDICARE/MEDICAID
-
$50,000 Jul 20, 2020 Issue: Medicare/Medicaid
-
$50,000 Apr 27, 2020 Issue: MEDICARE/MEDICAID
-
$50,000 Apr 17, 2020 Issue: Medicare/Medicaid
-
$30,000 Jan 21, 2020 Issue: MEDICARE/MEDICAID
-
$30,000 Jan 18, 2020 Issue: Medicare/Medicaid
-
$20,000 Mar 26, 2003 Issue: Copyright/Patent/Trademark
-
$20,000 Aug 22, 2002 Issue: Copyright/Patent/Trademark
-
$20,000 Mar 14, 2002 Issue: Copyright/Patent/Trademark
-
$60,000 Feb 20, 2002 Issue: None
-
$20,000 Sep 28, 2001 Issue: Copyright/Patent/Trademark
-
$60,000 Feb 15, 2000 Issue: Medical/Disease Research/Clinical Labs
-
$40,000 Aug 16, 1999 Issue: Medical/Disease Research/Clinical Labs
Estimated quarterly lobbying spending
U.S. Patents
New patents grants
-
Patent Title: Use of pyrazolopyrimidine derivatives for the treatment of pi3k-δ related disorders Nov. 26, 2024
-
Patent Title: Sustained release dosage forms for a jak1 inhibitor Nov. 26, 2024
-
Patent Title: Jak1 pathway inhibitors for the treatment of gastrointestinal disease Nov. 26, 2024
-
Patent Title: Heteroaryl amide compounds as sting activators Oct. 29, 2024
-
Patent Title: Bicyclic heterocycles as fgfr inhibitors Oct. 22, 2024
-
Patent Title: Biomarkers for graft-versus-host disease Sep. 24, 2024
-
Patent Title: Bicyclic amines as cdk12 inhibitors Sep. 10, 2024
-
Patent Title: Imidazotriazines and imidazopyrimidines as kinase inhibitors Sep. 10, 2024
-
Patent Title: Process of preparing a pd-1/pd-l1 inhibitor Sep. 10, 2024
-
Patent Title: Tricyclic urea compounds as jak2 v617f inhibitors Sep. 10, 2024
-
Patent Title: Bicyclic heterocycles as fgfr inhibitors Sep. 10, 2024
-
Patent Title: Imidazole and triazole kras inhibitors Sep. 03, 2024
-
Patent Title: Process and intermediates for preparing a jak inhibitor Aug. 27, 2024
-
Patent Title: Combination therapy comprising an fgfr inhibitor and a nectin-4 targeting agent Aug. 20, 2024
-
Patent Title: Cd73 inhibitor and a2a/a2b adenosine receptor inhibitor combination therapy Aug. 13, 2024
-
Patent Title: Salts of a pim kinase inhibitor Jul. 23, 2024
-
Patent Title: Imidazopyridazine and imidazopyridine compounds and uses thereof Jul. 09, 2024
-
Patent Title: Substituted imidazo[2,1-f][1,2,4]triazines as pi3k-gamma inhibitors Jul. 09, 2024
-
Patent Title: Pyrazoloquinoline kras inhibitors Jul. 09, 2024
-
Patent Title: Hetero-tricyclic compounds as inhibitors of kras Jul. 09, 2024
-
Patent Title: Crystalline solid forms of a bet inhibitor Jul. 09, 2024
-
Patent Title: Salts and processes of preparing a pi3k inhibitor Jul. 02, 2024
-
Patent Title: Salts of an fgfr inhibitor Jul. 02, 2024
-
Patent Title: Anti-cd73 antibodies and uses thereof Jun. 25, 2024
-
Patent Title: Bicyclic heterocycles as fgfr inhibitors Jun. 18, 2024
-
Patent Title: Heterocyclic derivatives as pi3k inhibitors Jun. 11, 2024
-
Patent Title: Jak inhibitor with a vitamin d analog for treatment of skin diseases Jun. 11, 2024
-
Patent Title: Vinyl imidazole compounds as inhibitors of kras Jun. 04, 2024
-
Patent Title: Bicyclic heteroarylaminoalkyl phenyl derivatives as pi3k inhibitors Jun. 04, 2024
-
Patent Title: Fused pyrazine derivatives as a2a / a2b inhibitors Jun. 04, 2024
-
Patent Title: Use of jak1 inhibitors for the treatment of cutaneous lupus erythematosus and lichen planus (lp) May. 28, 2024
-
Patent Title: Bicyclic pyrazolyl amines as cdk2 inhibitors May. 14, 2024
-
Patent Title: Bicyclic amines as cdk2 inhibitors May. 07, 2024
-
Patent Title: Spirocyclic lactams as jak2 v617f inhibitors Apr. 16, 2024
-
Patent Title: Jak1 pathway inhibitors for the treatment of vitiligo Apr. 16, 2024
-
Patent Title: Pyridine and pyridimine compounds as pi3k-gamma inhibitors Apr. 09, 2024
-
Patent Title: Tricyclic heterocycles as fgfr inhibitors Mar. 26, 2024
-
Patent Title: Quinoline compounds as inhibitors of kras Mar. 26, 2024
-
Patent Title: Tertiary alcohols as pi3k-γ inhibitors Mar. 12, 2024
-
Patent Title: Aminopyrazine diol compounds as pi3k-γ inhibitors Mar. 12, 2024
-
Patent Title: Substituted pyrrolo[2,3-d]pyrimidine compounds as jak2 v617f inhibitors Mar. 05, 2024
-
Patent Title: Sulfonylamide compounds as cdk2 inhibitors Mar. 05, 2024
-
Patent Title: Formulations of an axl/mer inhibitor Mar. 05, 2024
-
Patent Title: Combination therapy comprising jak pathway inhibitor and rock inhibitor Mar. 05, 2024
-
Patent Title: Tricyclic heteroaryl compounds as sting activators Feb. 27, 2024
-
Patent Title: Process and intermediates for preparing a jak inhibitor Feb. 20, 2024
-
Patent Title: Bipyrazole derivatives as jak inhibitors Feb. 20, 2024
-
Patent Title: Tricyclic heterocycles as fgfr inhibitors Feb. 13, 2024
-
Patent Title: Process and intermediates for preparing a jak1 inhibitor Feb. 13, 2024
-
Patent Title: Sustained-release dosage forms of ruxolitinib Feb. 13, 2024
Government Contracts
Federal grants, loans, and purchases
- $119,619 2024-07-02 00:00:00 Agency: Department of Veterans Affairs
- $541,104 2024-04-15 00:00:00 Agency: Department of Veterans Affairs
- $13,291 2024-03-15 00:00:00 Agency: Department of Veterans Affairs
- $13,291 2024-01-26 00:00:00 Agency: Department of Veterans Affairs
- $12,725 2024-01-12 00:00:00 Agency: Department of Veterans Affairs
- $12,725 2023-12-12 00:00:00 Agency: Department of Veterans Affairs
- $12,725 2023-11-29 00:00:00 Agency: Department of Veterans Affairs
- $12,725 2023-11-03 00:00:00 Agency: Department of Veterans Affairs
- $12,725 2023-09-25 00:00:00 Agency: Department of Veterans Affairs
- $12,874 2023-07-28 00:00:00 Agency: Department of Veterans Affairs
- $12,725 2023-06-13 00:00:00 Agency: Department of Veterans Affairs
- $12,874 2023-05-02 00:00:00 Agency: Department of Veterans Affairs
- $12,812 2023-04-20 00:00:00 Agency: Department of Veterans Affairs
- $675,000 2023-04-11 00:00:00 Agency: Department of Veterans Affairs
- $38,199 2023-03-15 00:00:00 Agency: Department of Veterans Affairs
- $82,626 2022-06-30 00:00:00 Agency: DEPARTMENT OF VETERANS AFFAIRS (VA)
- $76,351 2022-04-27 00:00:00 Agency: DEPARTMENT OF VETERANS AFFAIRS (VA)
- $499,918 2022-02-18 00:00:00 Agency: DEPARTMENT OF VETERANS AFFAIRS (VA)
- $0 2022-02-04 00:00:00 Agency: DEPARTMENT OF VETERANS AFFAIRS (VA)
- $320,250 2021-10-29 00:00:00 Agency: DEPARTMENT OF VETERANS AFFAIRS (VA)
- $12,725 2021-08-06 00:00:00 Agency: DEPARTMENT OF VETERANS AFFAIRS (VA)
- $12,725 2021-06-29 00:00:00 Agency: DEPARTMENT OF VETERANS AFFAIRS (VA)
- $101,802 2021-01-19 00:00:00 Agency: DEPARTMENT OF VETERANS AFFAIRS (VA)
- $114,527 2020-12-22 00:00:00 Agency: DEPARTMENT OF VETERANS AFFAIRS (VA)
- $0 2020-11-20 00:00:00 Agency: DEPARTMENT OF VETERANS AFFAIRS (VA)
- $12,725 2020-11-18 00:00:00 Agency: DEPARTMENT OF VETERANS AFFAIRS (VA)
- $12,725 2020-11-04 00:00:00 Agency: DEPARTMENT OF VETERANS AFFAIRS (VA)
- $12,725 2020-10-29 00:00:00 Agency: DEPARTMENT OF VETERANS AFFAIRS (VA)
- $12,725 2020-10-05 Agency: DEPARTMENT OF VETERANS AFFAIRS (VA)
- $12,725 2020-09-10 Agency: DEPARTMENT OF VETERANS AFFAIRS (VA)
Government Contracts
Estimated quarterly amount awarded from public contracts
WallStreetBets
Number of mentions of INCY in WallStreetBets Daily Discussion
INCY News
Recent insights relating to INCY
CNBC Recommendations
Recent picks made for INCY stock on CNBC
Top ETF Holders
ETFs with the largest estimated holdings in INCY
INCY Top Shareholders
|
Shareholder
|
Shares Held
|
|---|
* These are estimates based on data taken from SEC filings. There may be inaccuracies due to parsing errors, accidental double-counting, incorrect classification of indirectly owned shares, or any other number of issues.
INCY Stock Smart Score
The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.
The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.
?
Sign Up to view INCY Smart Score
Score Breakdown
Bull Case vs Bear Case
See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.
Example:
Bulls Say:
The Bulls Say summary highlights positive aspects of the stock.
Bears Say:
The Bears Say summary points out potential risks and negative aspects of the stock.
Show More